Passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic metabolic disorders


Agios (NASDAQ: AGIO) is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. In August 2017, Agios received approval from the FDA for IDHIFA® (enasidenib) for the treatment of adult patients with relapsed or refractory AML (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation, representing the first and only FDA-approved therapy for patients with R/R AML and an IDH2 mutation. IDHIFA was developed in collaboration with Celgene Corporation. In July 2018, Agios received approval from the FDA for TIBSOVO® (ivosidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test. TIBSOVO®, an oral, targeted inhibitor of the IDH1 enzyme, is the first and only FDA-approved therapy for patients with R/R AML and an IDH1 mutation. 


Year Invested: 2008
Location: Cambridge, Mass.
Visit: www.agios.com

Recent News

November 16, 2018
Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma

November 1, 2018
Agios to Present Updated Clinical Data at the 2018 ASH Annual Meeting

November 1, 2018
Agios Reports Third Quarter 2018 Financial Results

Read More News

Associated Team Members

Kevin Starr
Partner

Cary Pfeffer, M.D.
Partner